NVAX
Price:
$11.63
Market Cap:
$1.86B
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical...[Read more]
Industry
Biotechnology
IPO Date
1995-12-05
Stock Exchange
NASDAQ
Ticker
NVAX
According to Novavax, Inc.’s latest financial reports and current stock price. The company's current ROE is 43.70%. This represents a change of 641.83% compared to the average of 5.89% of the last 4 quarters.
The mean historical ROE of Novavax, Inc. over the last ten years is 592.64%. The current 43.70% ROE has changed -92.63% with respect to the historical average. Over the past ten years (40 quarters), NVAX's ROE was at its highest in in the December 2016 quarter at 1.03%. The ROE was at its lowest in in the September 2020 quarter at -185.37%.
Average
592.64%
Median
89.90%
Minimum
-68.16%
Maximum
5.05%
Discovering the peaks and valleys of Novavax, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 48.44%
Maximum Annual ROE = 5.05%
Minimum Annual Increase = -9514.06%
Minimum Annual ROE = -68.16%
Year | ROE | Change |
---|---|---|
2023 | 76.03% | -26.73% |
2022 | 103.76% | -79.07% |
2021 | 495.84% | -827.47% |
2020 | -68.16% | -197.45% |
2019 | 69.94% | -36.42% |
2018 | 110.01% | -39.10% |
2017 | 180.64% | -96.42% |
2016 | 5.05% | -9514.06% |
2015 | -53.62% | 48.44% |
2014 | -36.12% | 41.23% |
The current ROE of Novavax, Inc. (NVAX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
225.21%
5-year avg
135.48%
10-year avg
592.64%
Novavax, Inc.’s ROE is greater than Moderna, Inc. (-45.27%), greater than Inovio Pharmaceuticals, Inc. (-108.93%), greater than BioNTech SE (-2.57%), greater than Vaxart, Inc. (-114.19%), less than AstraZeneca PLC (16.80%),
Company | ROE | Market cap |
---|---|---|
-45.27% | $28.02B | |
-108.93% | $163.06M | |
-2.57% | $21.38B | |
-114.19% | $201.33M | |
16.80% | $257.50B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novavax, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novavax, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Novavax, Inc.'s ROE?
How is the ROE calculated for Novavax, Inc. (NVAX)?
What is the highest ROE for Novavax, Inc. (NVAX)?
What is the 3-year average ROE for Novavax, Inc. (NVAX)?
What is the 5-year average ROE for Novavax, Inc. (NVAX)?
How does the current ROE for Novavax, Inc. (NVAX) compare to its historical average?